Based on the above, inhibiting the metabolic advantage in RAS-driven tumors may improve treatment success, as seen with the use of sotorasib, a KRAS inhibitor that is currently approved for KRAS-mutated non-small-cell lung cancers [266]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.